Clinical Trial Update: A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating risk-enabled therapy after neoadjuvant immunochemotherapy for muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Muscle-Invasive Bladder Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING